- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03442855
Non-Interventional, Multicenter Bicontact® E PMCF Study
September 18, 2019 updated by: Aesculap AG
Prospective observational (non-interventional) cohort study, multi-centric in 5 study Centers in Japan to collect short term clinical and radiological results of the cementless Bicontact® E stem in a standard patient population used in routine clinical practice
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
73
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Funabashi, Japan
- Funabashi Orthopedic Hospital
-
Niigata, Japan
- Niigata Bandai Hospital
-
Niigata, Japan
- Niigata Rinko Hospital
-
Niigata, Japan
- Niigata Univ. Medical & Dental Hospital
-
Niigata, Japan
- Saiseikai Niigata Second Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients receiving primary THA:
Acute disorders of the hip that cannot be treated by other therapies:
- Degenerative osteoarthritis
- Rheumatic arthritis
- Joint fractures
- Femoral head necrosis
Description
Inclusion Criteria:
- Indication for Bicontact E prosthesis THA
- Patients ≥ 18 years
- Patient not pregnant
- Written informed consent
Exclusion Criteria:
- Patients receiving a bipolar implantation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Results
Time Frame: 1 year
|
Hip Score of the Japanese Orthopaedic Association (JOA): three categories-movement, mental, and pain-each comprising 7 items, for a total of 21 items to be used as evaluation criteria for hip-joint function
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Thigh Pain
Time Frame: 1 year
|
Pain as measured with the Visual Analog Scale (VAS): Visual analog scale [VAS] is a measure of pain intensity.
It is a continuous scale comprised of a horizontal analog scale of 100 mm length.
It is anchored by two verbal descriptors, one for each symptom extreme [no pain - worst imaginable pain].
|
1 year
|
|
X-Ray evaluation
Time Frame: 1 year
|
Radiological results (osteointegration, migration)
|
1 year
|
|
(Serious) Adverse Events
Time Frame: 1 year
|
Complications: Adverse Events (AE) / Serious Adverse Events (SAE)
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2017
Primary Completion (Actual)
May 31, 2018
Study Completion (Actual)
May 31, 2019
Study Registration Dates
First Submitted
February 6, 2018
First Submitted That Met QC Criteria
February 21, 2018
First Posted (Actual)
February 22, 2018
Study Record Updates
Last Update Posted (Actual)
September 19, 2019
Last Update Submitted That Met QC Criteria
September 18, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAG-O-H-1417
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
Yuanyuan ZhangRecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid ArthritisChina
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
-
David Grant U.S. Air Force Medical CenterCompleted